Meet Amprion’s CoFounders, CEO Russ Lebovitz and CSO Claudio Soto, talk candidly about the origin story of Amprion and their breakthrough science in prion detection. Amprion has developed proprietary technologies in tracking the misfolded proteins – Abeta, Tau, and Synuclein – the bad actors that cause Alzheimer’s, Parkinson’s and other neurodegenerative disease. Early detection is the keystone in finding the cure. Amprion’s revolutionary early detection technology aims to make a significant impact in Alzheimer’s—an escalating global health crisis.
Meet Amprion’s CoFounders
As neuroscience research experts, we study rare diseases like mad cow disease, that are very infectious diseases that can transmit from animals to humans, etc. We invented this technology that can detect misfolded proteins, it has potentially a very large application. One of the big breakthroughs conceptually for Amprion was understanding that Mad Cow disease that really Claudio had developed technology and Amprion was beginning to commercialize this technology, suddenly we could go from Mad Cow disease to other neurodegenerative diseases, it was just a small jump in a big step.
Today, scientists agree that there are more than 30 different diseases that involve the formation of this protein aggregate. Most are rare diseases but some of them like type 2 diabetes are very frequent, very prevalent diseases. We think cancer is also there. We believe that Amprion’s technology may actually be applicable to many many of the most common diseases in today. We believe that misfolding of proteins and the link between that misfolding of proteins in disease is, will be every bit as important in the future as somatic genetic changes, genetic mutations that occur that lead to cancer and other diseases.
Right now the tools are very advanced for analyzing genetic changes, somatic genetic changes, but at Amprion we are developing parallel tools for looking at all manner of misfolded proteins, individual proteins, different structures of those proteins, and we think there’s a personalized medicine approach to these diseases, using different structures of misfolded proteins, different combinations of misfolded proteins.
We’re trying to develop technology that can help physicians and drug companies to diagnose people and also develop early detection technologies for Alzheimer’s disease, Parkinson’s disease and other brain-related disorders. To me, to have a drug on the market that we help shepherd through, whether we invent it, or we just enable it, that is what would make me very excited. Science has a lot of powers. Let’s think about the most difficult things that you can think, and let’s work on those. Change the world, change society, improve life of people.